Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 520 entries
View as:

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)

Phase: N/A Priority: Normal
NCT ID: NCT06001268 Org: User:
Start: 08/14/23 End: 08/31/27 Due: 08/31/28

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Phase: N/A Priority: Normal
NCT ID: NCT06193486 Org: User:
Start: 02/26/24 End: 12/13/33 Due: 12/13/34

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

Phase: N/A Priority: Normal
NCT ID: NCT01671813 Org: User:
Start: 03/31/13 End: 07/31/13 Due: 07/31/14

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Phase: N/A Priority: Normal
NCT ID: NCT04620681 Org: User:
Start: 01/14/21 End: 07/20/25 Due: 07/20/26

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05358938 Org: User:
Start: 06/21/22 End: 12/31/25 Due: 12/31/26

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Phase: N/A Priority: Normal
NCT ID: NCT03630809 Org: User:
Start: 01/10/19 End: 04/11/22 Due: 04/11/23

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Phase: N/A Priority: Normal
NCT ID: NCT04242173 Org: User:
Start: 06/25/20 End: 05/26/22 Due: 05/26/23

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT02745756 Org: User:
Start: 04/14/16 End: 08/21/17 Due: 08/21/18

Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00803010 Org: User:
Start: 09/30/08 End: 12/31/12 Due: 12/31/13

Facilitating Smoking Cessation With Reduced Nicotine Cigarettes

Phase: N/A Priority: Normal
NCT ID: NCT02796391 Org: User:
Start: 09/07/17 End: 08/24/21 Due: 08/24/22

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT04252612 Org: User:
Start: 01/30/20 End: 06/26/23 Due: 06/26/24

Feasibility Study of Ultrasound Elastography Detecting Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03077126 Org: User:
Start: 04/11/13 End: 09/18/15 Due: 09/18/16

Applying mHealth to Tobacco-related Health Disparities

Phase: N/A Priority: Normal
NCT ID: NCT03404596 Org: User:
Start: 07/16/18 End: 12/14/20 Due: 12/14/21

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

Phase: N/A Priority: Normal
NCT ID: NCT00617409 Org: User:
Start: 10/02/07 End: 01/31/19 Due: 01/31/20

Digoxin Medulloblastoma Study

Phase: N/A Priority: Normal
NCT ID: NCT06701812 Org: User:
Start: 07/31/25 End: 02/28/27 Due: 02/28/28

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02061423 Org: User:
Start: 04/08/14 End: 02/21/24 Due: 02/21/25

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06660368 Org: User:
Start: 11/26/24 End: 11/30/27 Due: 11/30/28

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05665504 Org: User:
Start: 01/11/23 End: 02/29/28 Due: 02/28/29

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06435351 Org: User:
Start: 06/12/24 End: 05/31/29 Due: 05/31/30

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05651828 Org: User:
Start: 03/23/23 End: 12/31/29 Due: 12/31/30

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03387553 Org: User:
Start: 06/06/18 End: 08/29/26 Due: 08/29/27

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00694551 Org: User:
Start: 12/02/08 End: 12/06/18 Due: 12/06/19

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

Phase: N/A Priority: Normal
NCT ID: NCT00361140 Org: User:
Start: 08/31/05 End: 02/29/12 Due: 02/28/13

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00365222 Org: User:
Start: 07/31/06 End: 06/30/07 Due: 06/30/08

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00400569 Org: User:
Start: 11/30/06 End: 12/31/11 Due: 12/31/12